Publication Name	World Journal of Clinical Oncology
Manuscript ID	32579
Country	Peru

Received	2017-01-16 08:46
Peer-Review Started	2017-01-16 16:39
To Make the First Decision	2017-04-17 09:24
Return for Revision	2017-05-02 19:38
Revised	2017-08-11 23:59
Second Decision	2017-08-25 07:32
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-09-16 19:18
Articles in Press	2017-09-16 19:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-11-28 04:06
Publish the Manuscript Online	2017-12-05 00:35

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
Manuscript Source	Invited Manuscript
All Author List	Connie Rabanal, Rossana Ruiz, Silvia Neciosup and Henry Gomez
ORCID	Author(s) ORCID Number Connie Rabanal http://orcid.org/0000-0002-7807-3731
Funding Agency and Grant Number
Corresponding Author	Connie Rabanal, MD, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Lima 15038, Peru. connie.rabanal@hotmail.com
Key Words	Metronomic chemotherapy; Triple negative breast cancer; Neoadjuvant; Adjuvant; Maintenance
Core Tip	Triple negative breast cancer (TNBC) is the only type of breast cancer for which there are no approved targeted therapies. Metronomic chemotherapy (MC) is being explored as an alternative to improve outcomes in TNBC. In neoadjuvant setting, purely metronomic and hybrid approaches achieve complete pathologic response (pCR) rates between 47%-60%, but at the cost of great toxicity. In the adjuvant setting, MC is used to intensify adjuvant chemotherapy and, promisingly, as maintenance therapy for high-risk patients, especially those with no pCR. Considering the dismal prognosis of TNBC, any strategy that improves outcomes, specially being broadly available and inexpensive, should be considered.
Publish Date	2017-12-05 00:35
Citation	Rabanal C, Ruiz R, Neciosup S, Gomez H. Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key. World J Clin Oncol 2017; 8(6): 437-446
URL	http://www.wjgnet.com/2218-4333/full/v8/i6/437.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i6.437

Full Article (PDF)	WJCO-8-437.pdf
Full Article (Word)	WJCO-8-437.doc
Manuscript File	32579-Review.docx
Answering Reviewers	32579-Answering reviewers.pdf
Audio Core Tip	32579-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	32579-Conflict-of-interest statement.pdf
Copyright License Agreement	32579-Copyright assignment.pdf
Supplementary Material	Supplementary_Material_20170115052324.pdf
Peer-review Report	32579-Peer-review(s).pdf
Scientific Misconduct Check	32579-Scientific misconduct check.pdf
Scientific Editor Work List	32579-Scientific editor work list.pdf